2. Academic Validation
  3. Novel Non-hallucinogenic Neurite Growth Compounds as 5‑HT2A Agonists for Treating Stress-Related Disorders, Namely Depression, Anxiety, and PTSD

Novel Non-hallucinogenic Neurite Growth Compounds as 5‑HT2A Agonists for Treating Stress-Related Disorders, Namely Depression, Anxiety, and PTSD

  • ACS Med Chem Lett. 2025 Jul 30;16(8):1524-1525. doi: 10.1021/acsmedchemlett.5c00440.
Ram W Sabnis 1
Affiliations

Affiliation

  • 1 Smith, Gambrell & Russell LLP, 1105 W. Peachtree Street NE, Atlanta, Georgia 30309, United States.
PMID: 40832535 DOI: 10.1021/acsmedchemlett.5c00440
Abstract

Provided herein are novel non-hallucinogenic neurite growth compounds as 5-HT2A agonists, pharmaceutical compositions, use of such compounds in treating stress-related disorders, namely depression, anxiety, and post-traumatic stress disorder (PTSD), and processes for preparing such compounds.

Figures
Products